CLEARMIND MEDICINE INC (CMND) Fundamental Analysis & Valuation

NASDAQ:CMND • CA1850535016

Current stock price

0.737 USD
+0.02 (+2.36%)
At close:
0.7299 USD
-0.01 (-0.96%)
After Hours:

This CMND fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. CMND Profitability Analysis

1.1 Basic Checks

  • CMND had negative earnings in the past year.
  • CMND had a negative operating cash flow in the past year.
  • In the past 5 years CMND always reported negative net income.
  • CMND had a negative operating cash flow in each of the past 5 years.
CMND Yearly Net Income VS EBIT VS OCF VS FCFCMND Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2M -4M -6M -8M

1.2 Ratios

  • With a Return On Assets value of -102.00%, CMND is not doing good in the industry: 76.68% of the companies in the same industry are doing better.
  • CMND has a worse Return On Equity (-379.95%) than 78.24% of its industry peers.
Industry RankSector Rank
ROA -102%
ROE -379.95%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CMND Yearly ROA, ROE, ROICCMND Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500

1.3 Margins

  • CMND does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CMND Yearly Profit, Operating, Gross MarginsCMND Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. CMND Health Analysis

2.1 Basic Checks

  • CMND has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CMND Yearly Shares OutstandingCMND Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20K 40K 60K 80K 100K
CMND Yearly Total Debt VS Total AssetsCMND Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

2.2 Solvency

  • Based on the Altman-Z score of -12.94, we must say that CMND is in the distress zone and has some risk of bankruptcy.
  • CMND's Altman-Z score of -12.94 is on the low side compared to the rest of the industry. CMND is outperformed by 76.68% of its industry peers.
  • CMND has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -12.94
ROIC/WACCN/A
WACCN/A
CMND Yearly LT Debt VS Equity VS FCFCMND Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2M -2M -4M -6M

2.3 Liquidity

  • A Current Ratio of 1.32 indicates that CMND should not have too much problems paying its short term obligations.
  • CMND has a worse Current ratio (1.32) than 75.13% of its industry peers.
  • A Quick Ratio of 1.32 indicates that CMND should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.32, CMND is doing worse than 67.88% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.32
Quick Ratio 1.32
CMND Yearly Current Assets VS Current LiabilitesCMND Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. CMND Growth Analysis

3.1 Past

  • CMND shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 61.37%, which is quite impressive.
EPS 1Y (TTM)61.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.66%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

0

4. CMND Valuation Analysis

4.1 Price/Earnings Ratio

  • CMND reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CMND Price Earnings VS Forward Price EarningsCMND Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CMND Per share dataCMND EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CMND Dividend Analysis

5.1 Amount

  • No dividends for CMND!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CMND Fundamentals: All Metrics, Ratios and Statistics

CLEARMIND MEDICINE INC

NASDAQ:CMND (3/26/2026, 8:00:00 PM)

After market: 0.7299 -0.01 (-0.96%)

0.737

+0.02 (+2.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners0.44%
Inst Owner Change-97.63%
Ins Owners6.43%
Ins Owner Change0%
Market Cap1.11M
Revenue(TTM)N/A
Net Income(TTM)-4.05M
AnalystsN/A
Price TargetN/A
Short Float %9.37%
Short Ratio0.4
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.04
P/tB 1.14
EV/EBITDA N/A
EPS(TTM)-30.64
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-3.15
FCFYN/A
OCF(TTM)-3.02
OCFYN/A
SpS0
BVpS0.71
TBVpS0.64
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -102%
ROE -379.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.32
Quick Ratio 1.32
Altman-Z -12.94
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.66%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y1.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-4.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.1%
OCF growth 3YN/A
OCF growth 5YN/A

CLEARMIND MEDICINE INC / CMND Fundamental Analysis FAQ

What is the fundamental rating for CMND stock?

ChartMill assigns a fundamental rating of 1 / 10 to CMND.


What is the valuation status for CMND stock?

ChartMill assigns a valuation rating of 0 / 10 to CLEARMIND MEDICINE INC (CMND). This can be considered as Overvalued.


Can you provide the profitability details for CLEARMIND MEDICINE INC?

CLEARMIND MEDICINE INC (CMND) has a profitability rating of 0 / 10.